Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Jubilant Pharmova Revenue

Jubilant Pharmova had revenue of 22.29B INR in the quarter ending June 30, 2026, with 17.29% growth. This brings the company's total for the last twelve months to 86.08B, up 16.27% year-over-year. In the fiscal year ending March 31, 2026, Jubilant Pharmova had annual revenue of 82.80B with 14.45% growth.

• Revenue (ttm): 86.08B
• Revenue Growth: +16.27%
• P/S Ratio: 1.72
• Revenue / Employee: 15.22M
• Employees: 5,657
• Market Cap: 149.42B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Radio Pharma 36.90B 44.0%
• Contract Development and Manufacturing Organization - Sterile Injectables 18.13B 21.6%
• Contract Research, Development and Manufacturing Organization 12.65B 15.1%
• Allergy Immunotherapy 7.96B 9.5%
• Generics 7.74B 9.2%
• Unallocable Corporate 585.00M 0.7%

By Geography

Chart

• Americas and Europe 76.07B 91.9%
• Rest of The World (ROW) 4.27B 5.2%
• India 2.46B 3.0%

Fiscal year ended Mar 31, 2026 See the full Jubilant Pharmova breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	82.80B	10.45B	14.45%
Mar 31, 2025	72.35B	5.32B	7.93%
Mar 31, 2024	67.03B	4.21B	6.71%
Mar 31, 2023	62.82B	1.52B	2.47%
Mar 31, 2022	61.30B	316.29M	0.52%

Data Source: S&P Global Market Intelligence Last updated: Aug 10, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 16, 2026

Data Sources Report a data error